medigraphic.com
ISSN 1025-0255 (Electronic)

2016, Number 6

<< Back Next >>

AMC 2016; 20 (6)

Combined use of immunotherapy in a patient with kidney carcinoma: nine years later

Frías ÁG

Language: Spanish
References: 11
Page: 710-715
PDF size: 360.19 Kb.


ABSTRACT

Background: kidney cells carcinoma therapy is characterized by a poor response to adjuvant treatment.
Objective: to improve the free disease interval; global survive and quality of life.
Clinical Case: a sixty three- year-old patient with a right kidney carcinoma was operated in August 1998. In May, 2002 he was diagnosed with abdominal adenopathies. On November, 2002 he was operated again because ofdrenal metastases. On December, 2006 he began combined immunotherapy obtaining a complete response of him for the time being.
Conclusions: combined immunotherapy can be effective in the management of this type of tumor.


REFERENCES

  1. Infante Leyva R, Pedro Silva I, Matos Lobaina E, González González J. Protocolo de actuación asistencial en Neoplasias sólidas del parénquima renal. En: Villavicencio Negrín JA, editor. Manual de Prácticas Médicas del Hospital Hermanos Ameijeiras. 4 ed. La Habana: Editorial Ciencias Médicas; 2012. p. 183-194.

  2. Kong N, Cheung V. Therapeutic Antibodies and Immunological Conjugates. En: Nieder JE, editor. Abeloff’s Clinical Oncology. 5ta ed. Baltimore: Churcill Livingstone; 2014. p. 508-518.

  3. Negrier S, Escudier B, Lasset C. Recombinant human interleukin – 2, recombinant human interferon alfa - 2a or both in metastatic renal cell carcinoma. Group Francais d’ Inmunotherapie. N Engl J Med 1998;338:1272-8.

  4. Motzer RJ, Hudson TE, Cella D. Pazopanib versus Sunitinib in metastatic renal cell carcinoma. N Engl J Med 2013; 369: 722-731.

  5. Rini BI, Bellmunt J, Clancy J, Wang K, Niethamer A, Hariharan S, et al. Randomized Phase III Trial of Temsirolimus and Bebacizumab Versus Interferon alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. J Clin Oncol. 2014 Mar 10;32(8):752-9.

  6. Walter S, Weinschenk T, Stenzl A. Multipeptide immune response to cancer vaccine IMAP 901 after single-dose cyclophosphamide associates with longer patients survival. Nat Med. 2012;18:1254-61.

  7. Deng F, Melamed J, Zho M. Pathology of renal cell carcinoma. En: Libertino JA, editor. Renal Cancer: Contemporary Management. Fifth Edition. New York: Springer Science + Bussiness; 2013. p. 51-69.

  8. Rini BI, Dorff TB, Elson P, Suárez Rodríguez C, Shepard D, Wood L, et al. Active survellance in metastatic renal cell carcinoma a prospective phase 2 trial. N Engl J Med. 2016;17(9):1317-24.

  9. Scudier B, Eisen T, Porta C, Patard J, Khoo V, Algaba F, et al. Renal cell carcinoma: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow up. Annals of Oncology. 2012;23(7):65-71.

  10. Pili R, Kauff E, Rodríguez R. Cancer of the Kidney. En Nieder JE, editor. Abeloff’s Clinical Oncology. 5ta ed. Baltimore: Churcill Livingstone; 2014. p. 1416-43.

  11. Fish M, Seigne J. Immunotherapy of metastatic renal Cell Cancer. Cancer Control. 2002;9(4):293-5.




2020     |     www.medigraphic.com